Biotech

Biotech By Adam Feuerstein

STAT+ Conversations: A conversation on the latest in neuroscience and CNS drug development

Biotech By Adam Feuerstein

Sage drug reduces muscle tremor but with significant side effects, study results show

Biotech By Matthew Herper

Regeneron says antibody cocktail prevented Covid when given as simple injection, not an IV

Biotech By Matthew Herper

Lilly’s Retevmo shows success in rare tumors. But can doctors identify the patients who would be helped?

Biotech By Adam Feuerstein

iTeos Therapeutics debuts first data on TIGIT-targeting cancer immunotherapy

Biotech By Adam Feuerstein

Revolution Medicines seeks to bolster case for its lead cancer drug

Biotech By Damian Garde

Researchers see a ‘tractable approach’ to taming cancer metastasis

Biotech By Adam Feuerstein

Natural killer cells, primed with an antibody, induce remissions in patients with advanced blood cancer

Biotech By Rebecca Sohn

‘As good a model as I’ve seen’: MIT biologist on new initiative to address gender inequities in biotech

Biotech By Kate Sheridan

Biotech venture capitalists have more money than ever to invest. What could possibly go wrong?

Biotech By Adam Feuerstein

Fibrogen admits false heart-safety data for experimental anemia pill shared with FDA, investors

Biotech By Anissa Gardizy — Boston Globe

MIT scientists launch Future Founders Initiative to solve biotech’s ‘missing women’ problem

Biotech By Adam Feuerstein

FDA cites lack of evidence in rejecting Acadia Pharma’s bid to expand use of anti-psychosis drug

Biotech By Adam Feuerstein, Meg Tirrell, and Damian Garde

An antitrust expert weighs in on the FTC’s complaint against Illumina

Special Report By Brent Crane — The Wire

At BGI, China’s genomics giant, the line between biotech and Beijing is increasingly blurry

Biotech By Adam Feuerstein

Data for Delcath’s liver tumor device are positive, but lingering questions cloud path to approval

Biotech By Adam Feuerstein

The biotech scorecard for the second quarter: 18 stock-moving events to watch

Biotech By Damian Garde

STAT+ Conversations: A conversation on the future of gene therapy

Biotech By Damian Garde

A CRISPR 2.0 pioneer, expecting credit on its own invention, is ruffled by a competitor

Biotech By Matthew Herper

Humanigen says its drug keeps Covid patients off ventilators. But are some data missing?

Biotech By Adam Feuerstein

Uniqure investigation clears hemophilia B gene therapy as cause of patient’s liver cancer

Biotech By Adam Feuerstein

The future of cancer immunotherapy: your questions, answered

Biotech By Adam Feuerstein

FDA approves first personalized cell therapy for patients with multiple myeloma

Biotech By Damian Garde

FDA panel says risks of Pfizer pain drug outweigh the benefits

Biotech By Andy Rosen — Boston Globe

Broad Institute launches $300 million effort to harness AI to fight diseases

Adam's Take By Adam Feuerstein

A ‘conditional’ EUA for a CytoDyn Covid treatment? FDA says no such thing exists

Biotech By Adam Feuerstein

STAT Webinar: Future directions for cancer immunotherapy

Biotech By Mario Aguilar

STAT+ Conversations: A conversation about the challenges and advances in better hearing technology

Biotech By Kate Sheridan

Microbiome company Finch Therapeutics begins trading publicly, quietly shuffles one of its executives